2019新型冠状病毒病(COVID-19)疫情期间妇科恶性肿瘤放疗推荐

doi:10.3760/cma.j.cn113030-20200411-00172

Abstract
Figure/Table
References()
Related Citation (3)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract With the outbreak of COVID-19 around the globe, the epidemic prevention and control in China will take a long-term trend. As the main treatment of gynecological malignant tumor, rational application of radiotherapy bring patients with both “epidemic prevention” and “anti-tumor” benefits. This recommendation combined the domestic epidemic prevention guidelines, foreign literature related to epidemic prevention and gynecological tumor treatment, and the experiences of Peking Union Medical College Hospital during the prophase of epidemic period, aiming to provide guidance for the clinical work for radiotherapy and gynecological departments during COVID-19 crisis from the perspectives of gynecological radiotherapy principles, clinical trials, MDT and academic activities.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Yan Junfang
	Hu Ke
	Hou Xiaorong
	Li Gaofeng
	Jiang Ping
	Zhang Fuquan

Key words： COVID-19 Gynecological malignant tumor/radiotherapy Recommendation

Received: 11 April 2020

Corresponding Authors: Zhang Fuquan, Email:zhangfuquan3@126.com

Cite this article:

Yan Junfang,Hu Ke,Hou Xiaorong et al. Recommendation of radiotherapy for gynecological cancer during the COVID-19 epidemic[J]. Chinese Journal of Radiation Oncology, 2020, 29(9): 730-733.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20200411-00172 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2020/V29/I9/730

[1] Akladios C, Azais H, Ballester M, et al. Guidelines for surgical management of gynecological cancer during pandemic COVID-19 period-FRANCOGYN group for the CNGOF[J]. Gynecol Obstet Fertil Senol, 2020, 48(5):444-448. DOI:10.1016/j.gofs.2020.03.017.
[2] Ramirez PT, Chiva L, Eriksson AG, et al. COVID-19 global pandemic:options for management of gynecologic cancers[J]. Int J Gynecol Cancer, 2020, 30(5):561-563. DOI:10.1136/ijgc-2020-001419.
[3] Filippi AR, Russi E, Magrini SM, et al. Letter from Italy:First practical indications for radiotherapy departments during COVID-19 outbreak[J]. Int J Radiat Oncol Biol Phys, 2020, 107(3):597-599. DOI:10.1016/j.ijrobp.2020.03. 007.
[4] Gemici C,Yaprak G. Covid-19 outbreak in a major radiation oncology department;which lessons should be taken?[J]. Radiother Oncol, 2020, 149:107-108. DOI:10.1016/j.radonc.2020.03.044.
[5] Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients:a retrospective case study in three hospitals within Wuhan, China[J]. Ann Oncol, 2020, 31(7):894-901. DOI:10.1016/j.annonc.2020.03.296.
[6] The Royal College of Radiologists. The Royal College of Radiologists:timely delivery of radical radiotherapy:guidelines for the management of unscheduled treatment interruptions. 4 ed, 2019[M/OL][2020-04-09].https://www.rcr.ac.uk/publication/timelydelivery-radical-radiotherapy-guidelines-management-unscheduled-treatment.
[7] Rotz SJ, Leino D, Szabo S, et al. Severe cytokine release syndrome in a patient receiving PD-1-directed therapy[J]. Pediatr Blood Canc, 2017, 64(12):1-5. DOI:10.1002/pbc.26642.
[8] Peng L, Zagorac S, Stebbing J. Managing patients with cancer in the COVID-19 era[J]. Eur J Cancer, 2020,11(1):5-7. DOI:10.1016/j.ejca.2020.03.028.
[9] Mendez LC, Raziee H, Davidson M, et al. Should we embrace hypofractionated radiotherapy for cervical cancer? A technical note on management during the COVID-19 pandemic[J]. Raiother Oncol, 2020, 148(2):270-273. DOI:10.1016/j.radonc.2020.05.032.
[10] Assenholt MS, Petersen JB, Nielsen SK, et al. A dose planning study on applicator guided stereotactic IMRT boost in combination with 3d MRI based brachytherapy in locally advanced cervical cancer[J]. Acta Oncol, 2008, 47(7):1337-1343. DOI:10.1080/02841860802266698.
[11] Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer[J]. N Engl J Med, 1999, 340(15):1144-1153. DOI:10.1056/NEJM199904153401502.
[12] Saito T, Tabata T, Ikushima H, et al. Japan society of gynecologic oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer[J]. Int J Clin Oncol, 2018, 23(2):201-234. DOI:10.1007/s10147-017-1193-z.
[13] Yang K, Sheng Y, Huang C, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China:a multicenter, retrospective, cohort study[J]. Lancet Oncol, 2020, 21(7):904-913. DOI:10.1016/S1470-2045(20)30310-7.
[14] Schmid MP, Franckena M, Kirchheiner K, et al. Distant metastasis in patients with cervical cancer after primary radiotherapy with or without chemotherapy and image guided adaptive brachytherapy[J]. Gynecol Oncol, 2014, 133(2):256-262. DOI:10.1016/j.ygyno.2014.02.004.